HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Capricor Therapeutics (NASDAQ:CAPR) and maintained a $40 price target.

April 25, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Capricor Therapeutics with a $40 price target.
Reiteration of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance, potentially leading to positive investor sentiment and an upward movement in the stock's short-term price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100